Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Aged; Antipsychotic Agents /economics /therapeutic use; Chronic Disease; Cost-Benefit Analysis; Drug Costs /statistics & numerical data; Follow-Up Studies; Health Care Costs; Humans; Longitudinal Studies; Middle Aged; Patient Dropouts; Perphenazine /economics /therapeutic use; Psychiatric Status Rating Scales /statistics & numerical data; Quality-Adjusted Life Years; Research Design /standards /statistics & numerical data; Schizophrenia /diagnosis /drug therapy /economics; Schizophrenic Psychology; Treatment Outcome

AccessionNumber
22007000319

Date bibliographic record published
27/02/2007